We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Middlebrook Pharmaceuticals (MM) | NASDAQ:MBRK | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.1335 | 0 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 20, 2010
MIDDLEBROOK PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 000-50414 | 52-2208264 | ||
(State or other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
7 Village Circle, Suite 100, Westlake, Texas
|
76262 | |
(Address of Principal Executive Offices) | (Zip Code) |
Registrants telephone number, including area code: (817) 837-1200
N/A
|
(Former name or former address if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
1
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) On March 20, 2010, James H. Cavanaugh, Ph.D. and Harold R. Werner resigned from their positions as members of the board of directors (the Board) of MiddleBrook Pharmaceuticals, Inc. (MiddleBrook or the Company). In addition, on March 22, 2010, Martin A. Vogelbaum resigned from his position as a member of the Board. There were no disagreements between Dr. Cavanaugh, Mr. Vogelbaum or Mr. Werner and the Company.
The Board appointed new members to its Compensation Committee and Nominating and Governance Committee on March 23, 2010 to fill the vacancies created by the resignations. The Board appointed Richard W. Dugan, an existing independent member of the Board, as a member of the Companys Compensation Committee to fill the vacancy created by Mr. Vogelbaums resignation. The Board appointed Mark R. Sotir and William C. Pate, also existing independent Board members, to the Nominating and Governance Committee to fill the vacancies created by the resignations of Dr. Cavanaugh and Mr. Werner.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
||
|
MIDDLEBROOK PHARMACEUTICALS, INC. | |
|
||
Date: March 23, 2010
|
By: | /s/ David Becker |
|
||
|
David Becker | |
|
Executive Vice President and Chief Financial Officer
and Acting President and Chief Executive Officer |
3
1 Year Middlebrook Pharmaceuticals (MM) Chart |
1 Month Middlebrook Pharmaceuticals (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions